Genetic Targets Open the Door to New Treatment Options in Kidney Cancer
Discovering different genetic mutations to target ... continues to add to
Running the Race of Cancer
Going through cancer is a marathon, not a sprint.
Becoming an Active Participant in Kidney Cancer Care
As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.
The Silver Lining of Failure in Cancer Drug Development
One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.
Sarcomatoid Renal Cell Carcinoma: From Limited Options to a 'Game Changer'
FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.
A Sea Change in Treatment for von Hippel-Lindau Disease
HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.
Risk Versus Reward: Managing Side Effects of Kidney Cancer Treatments
Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.
2 Clarke Drive Cranbury, NJ 08512